In our study, the entire BCR/ABL gene was sequenced including the SH3-SH2 domain, cap region and the ABL kinase domain and the overall incidence of mutations in 94 CML patients with imatinib resistance was 44% (41/94), at the median of 40 months (range 3–96 months). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.